| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Inhibition of Epstein-Barr Virus Early Antigen (EBV-EA) induction by tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA); the half-maximal inhibitory concentration (IC50) for 3,29-O-dibenzoyloxykarounidiol was 0.8 μM [1]
|
|---|---|
| ln Vitro |
3,29-O-dibenzoyloxykarounidiol showed inhibitory activity against the expression of Epstein-Barr Virus Early Antigen (EBV-EA) induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells (a human B-lymphoblastoid cell line that harbors EBV). When tested at different concentrations, the compound was able to reduce the proportion of EBV-EA-positive cells. Through dose-response analysis, the half-maximal inhibitory concentration (IC50) of 3,29-O-dibenzoyloxykarounidiol for TPA-induced EBV-EA induction was determined to be 0.8 μM. This inhibitory effect indicated that 3,29-O-dibenzoyloxykarounidiol might possess potential anti-tumor-promoting properties, as TPA-induced EBV-EA expression is a well-recognized in vitro indicator for evaluating anti-tumor-promoting activity [1]
|
| Cell Assay |
The cell-based assay to assess the inhibitory effect of 3,29-O-dibenzoyloxykarounidiol on TPA-induced EBV-EA expression was conducted as follows: First, Raji cells were cultured in a suitable growth medium under standard in vitro cell culture conditions (maintained at 37°C in a humidified atmosphere with 5% CO2). After reaching the appropriate growth phase, the cells were harvested and adjusted to a specific cell density. The adjusted cell suspension was then seeded into multi-well cell culture plates. Next, different concentrations of 3,29-O-dibenzoyloxykarounidiol were added to the respective wells containing the Raji cells. Following the addition of the compound, TPA was introduced into each well to initiate the induction of EBV-EA expression. The cells were then incubated continuously for 48 hours under the aforementioned standard culture conditions. After the incubation period, the cells were fixed using a suitable fixative to preserve their morphology and cellular components. Subsequently, immunofluorescence staining was performed: the fixed cells were first incubated with a primary antibody that specifically binds to EBV-EA, and after washing to remove unbound primary antibody, a fluorescently labeled secondary antibody (that recognizes the primary antibody) was added. After another round of washing, the wells were observed under a fluorescence microscope. The number of cells exhibiting positive fluorescence (indicating EBV-EA expression) was counted manually or using image analysis software. The percentage of EBV-EA-positive cells in each well was calculated by dividing the number of positive cells by the total number of cells in that well. The inhibitory rate of each concentration of 3,29-O-dibenzoyloxykarounidiol was calculated by comparing the percentage of EBV-EA-positive cells in the compound-treated group with that in the control group (which received only TPA without the compound). Finally, a dose-response curve was constructed by plotting the inhibitory rates against the corresponding concentrations of 3,29-O-dibenzoyloxykarounidiol, and the IC50 value was derived from this curve using appropriate statistical or curve-fitting methods [1]
|
| References | |
| Additional Infomation |
3,29-O-dibenzoyloxykarounidiol is a triterpenoid compound isolated from the fruit of Monk Fruit (Momordica grosvenori). This study aims to investigate the antitumor activity of cucurbitane glycosides and other triterpenoid components extracted from Monk Fruit. Epstein-Barr virus (EBV) is closely related to the occurrence and development of various human malignant tumors, and 12-O-tetradecanoylphorbol-13-acetate (TPA) is a classic tumor promoter that can effectively induce the expression of EBV-EA in Raji cells. Therefore, the inhibitory effect of 3,29-O-dibenzoyloxykarounidiol on TPA-induced EBV-EA expression provides preliminary evidence for its potential role as an antitumor promoter [1].
|
| Molecular Formula |
C44H56O4
|
|---|---|
| Molecular Weight |
648.93
|
| Exact Mass |
648.417
|
| CAS # |
389122-01-4
|
| PubChem CID |
10919365
|
| Appearance |
White to off-white solid
|
| LogP |
11.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
48
|
| Complexity |
1330
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@@](C[C@H]1[C@@]3(CC=C4C(=CC[C@@H]5[C@@]4(CC[C@H](C5(C)C)OC(=O)C6=CC=CC=C6)C)[C@]3(CC2)C)C)(C)COC(=O)C7=CC=CC=C7
|
| InChi Key |
RTSZUVCSDUONDF-GJSTXJOSSA-N
|
| InChi Code |
InChI=1S/C44H56O4/c1-39(2)34-19-18-33-32(42(34,5)22-21-36(39)48-38(46)31-16-12-9-13-17-31)20-23-44(7)35-28-40(3,24-25-41(35,4)26-27-43(33,44)6)29-47-37(45)30-14-10-8-11-15-30/h8-18,20,34-36H,19,21-29H2,1-7H3/t34-,35+,36+,40+,41+,42+,43+,44-/m0/s1
|
| Chemical Name |
[(2R,4aS,6aS,8aR,10R,12aS,14aS,14bR)-10-benzoyloxy-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicen-2-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5410 mL | 7.7050 mL | 15.4100 mL | |
| 5 mM | 0.3082 mL | 1.5410 mL | 3.0820 mL | |
| 10 mM | 0.1541 mL | 0.7705 mL | 1.5410 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
